BR112023019433A2 - Tratamentos de combinação para melanoma - Google Patents
Tratamentos de combinação para melanomaInfo
- Publication number
- BR112023019433A2 BR112023019433A2 BR112023019433A BR112023019433A BR112023019433A2 BR 112023019433 A2 BR112023019433 A2 BR 112023019433A2 BR 112023019433 A BR112023019433 A BR 112023019433A BR 112023019433 A BR112023019433 A BR 112023019433A BR 112023019433 A2 BR112023019433 A2 BR 112023019433A2
- Authority
- BR
- Brazil
- Prior art keywords
- melanoma
- combination treatments
- combination
- treatments
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166295P | 2021-03-26 | 2021-03-26 | |
| US202163208728P | 2021-06-09 | 2021-06-09 | |
| PCT/EP2022/057895 WO2022200557A1 (en) | 2021-03-26 | 2022-03-25 | Combination treatments for melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023019433A2 true BR112023019433A2 (pt) | 2023-10-24 |
Family
ID=81449142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023019433A BR112023019433A2 (pt) | 2021-03-26 | 2022-03-25 | Tratamentos de combinação para melanoma |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197748A1 (https=) |
| EP (1) | EP4313057A1 (https=) |
| JP (1) | JP2024512558A (https=) |
| KR (1) | KR20230162030A (https=) |
| AU (2) | AU2022245277B8 (https=) |
| BR (1) | BR112023019433A2 (https=) |
| CA (1) | CA3213407A1 (https=) |
| IL (1) | IL306028A (https=) |
| MX (1) | MX2023011332A (https=) |
| TW (1) | TW202304458A (https=) |
| WO (1) | WO2022200557A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297842A (en) * | 2020-05-11 | 2023-01-01 | Astrazeneca Ab | ATR inhibitors for cancer treatment |
| WO2025233224A1 (en) * | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| WO2015036499A1 (en) * | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| IL297842A (en) * | 2020-05-11 | 2023-01-01 | Astrazeneca Ab | ATR inhibitors for cancer treatment |
-
2022
- 2022-03-25 AU AU2022245277A patent/AU2022245277B8/en active Active
- 2022-03-25 BR BR112023019433A patent/BR112023019433A2/pt unknown
- 2022-03-25 EP EP22719807.4A patent/EP4313057A1/en active Pending
- 2022-03-25 KR KR1020237036562A patent/KR20230162030A/ko active Pending
- 2022-03-25 IL IL306028A patent/IL306028A/en unknown
- 2022-03-25 WO PCT/EP2022/057895 patent/WO2022200557A1/en not_active Ceased
- 2022-03-25 US US18/552,300 patent/US20240197748A1/en active Pending
- 2022-03-25 MX MX2023011332A patent/MX2023011332A/es unknown
- 2022-03-25 TW TW111111247A patent/TW202304458A/zh unknown
- 2022-03-25 JP JP2023558347A patent/JP2024512558A/ja active Pending
- 2022-03-25 CA CA3213407A patent/CA3213407A1/en active Pending
-
2025
- 2025-10-16 AU AU2025252564A patent/AU2025252564A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL306028A (en) | 2023-11-01 |
| WO2022200557A1 (en) | 2022-09-29 |
| KR20230162030A (ko) | 2023-11-28 |
| CA3213407A1 (en) | 2022-09-29 |
| AU2025252564A1 (en) | 2025-11-27 |
| MX2023011332A (es) | 2023-10-03 |
| JP2024512558A (ja) | 2024-03-19 |
| US20240197748A1 (en) | 2024-06-20 |
| EP4313057A1 (en) | 2024-02-07 |
| AU2022245277A9 (en) | 2023-11-16 |
| TW202304458A (zh) | 2023-02-01 |
| AU2022245277B1 (en) | 2025-07-17 |
| AU2022245277A1 (en) | 2023-11-02 |
| AU2022245277B8 (en) | 2025-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| MX2018003824A (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control. | |
| BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
| BR112021024532A2 (pt) | Terapia combinada anticâncer | |
| MX390517B (es) | Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion. | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| EA201891607A1 (ru) | Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований | |
| BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
| MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
| MX388474B (es) | Composiciones que contienen tucaresol o sus análogos. | |
| BRPI0606542A2 (pt) | métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
| MX2015011466A (es) | Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. | |
| MX2022007962A (es) | Anticuerpo anti-lilrb1 y usos del mismo. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2019011657A (es) | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. | |
| MX2020003270A (es) | Combinacion de un inhibidor de btk y un inhibidor de cdk9 para tratar el cancer. | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112023019433A2 (pt) | Tratamentos de combinação para melanoma | |
| MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| BR112017023855A2 (pt) | o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc) | |
| MX2018008732A (es) | Inhibicion de la reaccion alergica usando un inhibidor de il-33. |